Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Fluarix Quadrivalent in Adults
NCT01204671Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2010
- Primary completion
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of influenza virus vaccine, quadrivalent, split virion in influenza (5 arms), sponsored by GSK. Primary endpoints: Titers for Hemagglutination Inhibition (HI) Antibodies at Day 21 and Number of Seroconverted Subjects at Day 21. Started Oct 2010; status: completed.
02
Drugs
influenza virus vaccine, quadrivalent, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01204671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204671.